Get the Stockscreener App
87.53
1.45%
1.3617
Intra Cellular Therapies Inc stock is traded at $87.53, with a volume of 150.71K.
It is up +1.45% in the last 24 hours and up +19.93% over the past month.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
See More
Previous Close:
$86.17
Open:
$85.79
24h Volume:
150.71K
Relative Volume:
0.27
Market Cap:
$9.20B
Revenue:
$563.44M
Net Income/Loss:
$-84.30M
P/E Ratio:
-54.37
EPS:
-1.61
Net Cash Flow:
$-61.23M
1W Performance:
+13.90%
1M Performance:
+19.93%
6M Performance:
+27.06%
1Y Performance:
+58.97%
1-Day Range:
$85.08
$87.74
1-Week Range:
$76.76
$88.00
52-Week Range:
$52.88
$88.00
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Name
Intra Cellular Therapies Inc
Sector
Phone
(646) 440-9333
Address
135 ROUTE 202/206, BEDMINSTER, NY
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-06-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-11-23 | Initiated | TD Cowen | Outperform |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Aug-22-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-22-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Initiated | Goldman | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-10-20 | Initiated | Goldman | Buy |
| Feb-20-20 | Initiated | Evercore ISI | Outperform |
| Jan-31-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-24-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-12-19 | Initiated | Jefferies | Buy |
| Feb-26-18 | Initiated | JP Morgan | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Nov-08-17 | Upgrade | SunTrust | Hold → Buy |
| Sep-07-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-30-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Aug-24-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Aug-23-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-02-17 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| May-02-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| May-01-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-16 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-29-16 | Downgrade | SunTrust | Buy → Neutral |
View All
Intra Cellular Therapies Inc Stock (ITCI) Latest News
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63% - Benzinga
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial - Reuters
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia - The Manila Times
Intra-Cellular Therapies Announces Positive Topline Results - GlobeNewswire
Allspring Global Investments Holdings LLC Has $136,000 Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies' SWOT analysis: CAPLYTA drives stock potential amid market expansion - Investing.com
Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews - Benzinga
Intra-Cellular Therapies (NASDAQ:ITCI) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
What is Leerink Partnrs' Estimate for ITCI FY2024 Earnings? - MarketBeat
Emerald Advisers LLC Acquires 48,705 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
(ITCI) Technical Pivots with Risk Controls - Stock Traders Daily
Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results - Yahoo Finance
FY2027 Earnings Estimate for ITCI Issued By Leerink Partnrs - MarketBeat
Intra-Cellular Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
abrdn plc Has $18.36 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Sees Large Decrease in Short Interest - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High at $85 By Investing.com - Investing.com Australia
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2024 Earnings Call Transcript - Insider Monkey
Intra-Cellular: Q3 Earnings Snapshot - The Pioneer
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales - MSN
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $96.62 Average Target Price from Brokerages - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High at $85 - Investing.com India
Intra-Cellular Therapies Reports Strong Q3 Growth - TipRanks
Intra-Cellular stock target raised on Caplyta sales outlook By Investing.com - Investing.com Canada
Intra-Cellular jumps on Q3 beat as Caplyta outlook brightens - MSN
Intra-Cellular Therapies Q3 2024 Earnings Preview - MSN
Intra-Cellular stock jumps on Caplyta outlook (ITCI:NASDAQ) - Seeking Alpha
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 1-Year HighStill a Buy? - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance - The Manila Times
Intra-Cellular Therapies Reports Third Quarter 2024 - GlobeNewswire
Intra-Cellular Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Earnings Preview For Intra-Cellular Therapies - Benzinga
China Universal Asset Management Co. Ltd. Increases Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
What To Expect From Intra-Cellular Therapies Inc (ITCI) Q3 2024 Earnings - GuruFocus.com
Intra-Cellular Therapies, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Marketscreener.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Lecap Asset Management Ltd. Acquires Shares of 6,815 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Intra-Cellular Therapies (ITCI) Scheduled to Post Earnings on Wednesday - MarketBeat
(ITCI) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by SG Americas Securities LLC - MarketBeat
Leerink Partnrs Issues Pessimistic Outlook for ITCI Earnings - MarketBeat
Cwm LLC Increases Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Brokers Issue Forecasts for Intra-Cellular Therapies, Inc.'s FY2025 Earnings (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast - The Manila Times
Morgan Stanley Raises Intra-Cellular Therapies (NASDAQ:ITCI) Price Target to $95.00 - Defense World
Potential Price Increase for Intra-Cellular Therapies Inc (ITCI) After Recent Insider Activity - Knox Daily
Intra-Cellular Therapies (NASDAQ:ITCI) delivers shareholders enviable 55% CAGR over 5 years, surging 6.4% in the last week alone - Simply Wall St
Intra Cellular Therapies Inc Stock (ITCI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Intra Cellular Therapies Inc Stock (ITCI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mates Sharon | Chairman and CEO |
Aug 29 '24 |
Option Exercise |
12.73 |
35,604 |
453,239 |
1,105,933 |
| Mates Sharon | Chairman and CEO |
Aug 30 '24 |
Option Exercise |
12.73 |
34,396 |
437,861 |
1,104,725 |
| Mates Sharon | Chairman and CEO |
Aug 29 '24 |
Sale |
72.57 |
35,604 |
2,583,884 |
1,070,329 |
| Mates Sharon | Chairman and CEO |
Aug 30 '24 |
Sale |
72.84 |
34,396 |
2,505,351 |
1,070,329 |
1.43%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):